Is Panacea Biotec Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Panacea Biotec Ltd (PANACEABIO.NS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Panacea Biotec Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Panacea Biotec Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Panacea Biotec Ltd?

Muslim investors may consider investing in Panacea Biotec Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Panacea Biotec Ltd classified as HALAL?

Musaffa determines the Shariah status of Panacea Biotec Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Panacea Biotec Ltd updated?

The Shariah compliance status of Panacea Biotec Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Panacea Biotec Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Panacea Biotec Ltd?

You can check the latest Shariah compliance status of Panacea Biotec Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

PANACEABIO.NS Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: March 06, 2026

Report Source: 2026 3rd Quarter Report

Panacea Biotec Ltd. Stock Analysis PANACEABIO.NS

India Health Care Micro Cap Report: Q3, 2026

Panacea Biotec Ltd. is a biotechnology company, which engages in the business of research, development, manufacture, and marketing of vaccines and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi and currently employs 1,290 full-time employees. The firm is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. The company has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.

Key Statistics of Panacea Biotec Ltd (PANACEABIO.NS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

₹368.00₹379.75

Today's Open

₹360.20

Volume

68.83K

P/E Ratio (TTM)

52 Week Range

₹292.40₹581.90

Market Cap

22.81B

Avg. Volume

134.45K

Dividend Yield

Financial Metrics & Statements of Panacea Biotec Ltd (PANACEABIO.NS)

FAQ's for Panacea Biotec Ltd (PANACEABIO.NS)

According to Musaffa’s Shariah screening methodology, Panacea Biotec Ltd (PANACEABIO.NS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.